NCT02092909 2019-09-10
8400-401
Idera Pharmaceuticals, Inc.
Phase 1/2 Terminated
Clinical Trials
3 trialsNCT02363439 2018-01-09
Extension Study of IMO-8400 in Patients With Waldenström's Macroglobulinemia Who Completed Study 8400-401
Idera Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT02252146 2017-12-12
Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88 L265P Mutation
Idera Pharmaceuticals, Inc.
Phase 1/2 Completed